The prognosis of patients with colon cancer harboring a mutation in the BRAF-V600 gene is markedly poor. If the therapy does not work, the probability of survival is only four to six months. Triple therapy can at least slightly improve them.
The prognosis of patients with colon cancer harboring a mutation in the BRAF-V600 gene is markedly poor. If the therapy does not work, the probability of survival is only four to six months. Triple therapy can at least slightly improve them.
Input your search keywords and press Enter.